BLOOD CLOTTING PROTEINS

最初的纤维蛋白原研究是我们最古老的合作之一。 人类突变产生血友病由于一个单一的氨基酸 纤维蛋白原的变化称为纤维蛋白原梅斯。 我们把这个地方 与Au，，并将其定位到高分辨率与干。 其他 研究标记纤维蛋白原上的非共价聚合位点， 合成与之结合的四肽， 这五肽还特异性靶向 “聚合位点，现在已经被Au标记， 地图这个网站。 这证明了这些技术在映射 重要功能亚分子位点和结构域 分辨率 . 我们还在研究形成 使用以各种方式修饰或标记的纤维蛋白原的纤维蛋白聚合物 与集群。 关于纤维蛋白早期中间体的论文 聚合反应已经公开。“：纳米金已被用于标记 凝血酶以绘制其在纤维蛋白原上的结合位点。 标签有 一直很好，但多余的黄金一直难以消除，所以映射 还没有定论 凝血因子VM是血友病的缺陷。 巴克斯特医疗保健公司在不同的表达系统中克隆了它。 他们 我感兴趣的是将这些系统的VHI因子与 一种来自人血浆。

The original fibrinogen study is one of our oldest collaborations. A human mutation produces a hemophilia due to a single amino acid change in fibrinogen called fibrinogen Metz. We labeled this site with Au, , and localized it to high resolution with the STEM. Other studies label the non-covalen0epolymerization sites on fibrinogen by synthesizing the tetrapeptide that binds there and adding a cysteine for gold attachment This pentapeptide also specifically targets the"epolymerization site and has now been Au-labeled to structurally map this site. This demonstrates the power of these techniques to map important functional subrnolecular sites and domain at high resolution. . We are also studying intermediates in the formation of fibrin polymers using fibrinogen modified in various ways or labeled with clusters. A paper on early intermediates in fibrin polymerization has been published.': Nanogold has been used to label thrombin to map its binding site(s) on fibrinogen. The labeling has been good, but excess gold has been difficult to remove so the mapping is still inconclusive. Factor VM is what is defective in hemophilia. Baxter Healthcare has it cloned in different expression systems. They am interested in compared the factor VHI from these systems with the one from human plasma.